Law360, New York (July 12, 2012, 11:53 AM ET) -- Watson Pharmaceuticals Inc. said Thursday that the Federal Trade Commission has asked for further information about its €4.25 billion ($5.2 billion) plan to buy Swiss drugmaker Actavis Group as the agency reviews possible anti-competitive effects of the deal.
The competition watchdog's request comes under the Hart–Scott–Rodino Antitrust Improvements Act's notification requirements, and will extend the merger waiting period under the act, Watson said. The tie-up, announced in April, will create the world's third-largest generic pharmaceuticals maker.
"Watson intends to cooperate fully with the FTC's review and...
FTC Seeks More Info On $5.2B Watson, Actavis Merger
To view the full article, take a free trial now.
